​

Larimar Therapeutics (LRMR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LRMR Stock Forecast

Larimar Therapeutics (LRMR) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 61.29% increase from the last price of $4.34.

$3 $4 $5 $6 $7 $8 $9 $10 $11 $12 High: $7 Avg: $7 Low: $7 Last Closed Price: $4.34

LRMR Stock Rating

Larimar Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

LRMR Price Target Upside V Benchmarks

TypeNameUpside
StockLarimar Therapeutics61.29%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts113
Avg Price Target$7.00$7.00$12.00
Last Closing Price$4.34$4.34$4.34
Upside/Downside61.29%61.29%176.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25110---11
Sep, 25110---11
Aug, 25110---11
Jul, 25110---11
Jun, 25110---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 30, 2025Joel BeattyRobert W. Baird$7.00$3.38107.10%61.29%
Dec 17, 2024Edward WhiteH.C. Wainwright$15.00$4.28250.47%245.62%
Oct 30, 2024Samantha SemenkowCitigroup$14.00$8.4665.48%222.58%
Oct 03, 2024Laura ChicoWedbush$22.00$6.29249.76%406.91%
Apr 03, 2024Joori ParkLeerink Partners$25.00$7.57230.25%476.04%
Dec 13, 2022Citigroup$4.00$3.970.76%-7.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2025OppenheimerOutperformOutperformhold
Jun 24, 2025CitigroupBuyBuyhold
Mar 25, 2025CitigroupBuyBuyhold
Dec 17, 2024H.C. WainwrightBuyBuyhold
Oct 30, 2024CitigroupBuyBuyhold
Oct 15, 2024OppenheimerOutperforminitialise
Oct 03, 2024WedbushOutperforminitialise
Oct 02, 2024H.C. WainwrightBuyinitialise
May 22, 2024CitigroupBuyBuyhold
May 21, 2024William BlairOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.84$-1.32----
Avg Forecast$-0.74$-1.22$-1.65$-1.98$-1.52$-0.27
High Forecast$-0.70$-1.16$-1.24$-0.92$-0.21$-0.27
Low Forecast$-0.78$-1.26$-1.99$-2.89$-2.48$-0.27
Surprise %13.51%8.20%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$15.52M$82.32M$216.52M
High Forecast---$15.52M$84.43M$216.52M
Low Forecast---$15.52M$80.22M$216.52M
Surprise %------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.95M$-80.60M----
Avg Forecast$-32.48M$-53.15M$-70.87M$-83.57M$-106.67M$-11.85M
High Forecast$-30.68M$-51.08M$-54.33M$-40.22M$-9.04M$-11.85M
Low Forecast$-34.27M$-55.23M$-87.41M$-126.92M$-108.93M$-11.85M
Surprise %13.77%51.64%----

LRMR Forecast FAQ

Is Larimar Therapeutics stock a buy?

Larimar Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Larimar Therapeutics is a favorable investment for most analysts.

What is Larimar Therapeutics's price target?

Larimar Therapeutics's price target, set by 8 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 61.29% change from the previous closing price of $4.34.

How does Larimar Therapeutics stock forecast compare to its benchmarks?

Larimar Therapeutics's stock forecast shows a 61.29% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Larimar Therapeutics over the past three months?

  • October 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Larimar Therapeutics’s EPS forecast?

Larimar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.65, marking a 25.00% increase from the reported $-1.32 in 2024. Estimates for the following years are $-1.98 in 2026, $-1.52 in 2027, and $-0.27 in 2028.

What is Larimar Therapeutics’s revenue forecast?

Larimar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $15.52M, followed by $82.32M for 2027, and $216.52M for 2028.

What is Larimar Therapeutics’s net income forecast?

Larimar Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-70.87M, representing a -12.08% decrease from the reported $-80.604M in 2024. Projections indicate $-83.568M in 2026, $-107M in 2027, and $-11.853M in 2028.